White Paper AGA: Gastroparesis: Clinical and Regulatory Insights for Clinical Trials
- PMID: 28410896
- PMCID: PMC6642744
- DOI: 10.1016/j.cgh.2017.04.011
White Paper AGA: Gastroparesis: Clinical and Regulatory Insights for Clinical Trials
Abstract
Gastroparesis continues to represent a large unmet clinical need and a major opportunity for new drug development. This has led to increasing interest by federal funding agencies, regulatory bodies, and industry. This article summarizes the proceedings of the gastroparesis section of the "Drug Development Conference: Clinical Endpoints in Upper GI Disorders" organized by the American Gastroenterological Association in Washington, DC, on October 27-28, 2016. The presentation, diagnosis, and current therapeutic strategies are briefly reviewed, followed by a detailed discussion of the regulatory strategy, recommended endpoints, and future directions.
Keywords: Clinical Trial Design; Endpoints; Gastroparesis.
Copyright © 2017 AGA Institute. Published by Elsevier Inc. All rights reserved.
References
-
- Revicki DA, Camilleri M, Kuo B, et al. Development and content validity of a gastroparesis cardinal symptom index daily diary. Aliment Pharmacol Ther 2009;30:670–680. - PubMed
-
- Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000;95:1456–1462. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous